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Introduction
Together with chronic hepatitis B, chronic hepatitis C (CHC) is a leading cause of death and disability worldwide. [1] The enormous health cost attributable to viral hepatitis and the availability of effective treatments suggests an important opportunity to improve public health, especially in the case of CHC now that a simple and well-tolerated therapeutic cure is available. As part of a global strategy for eliminating viral hepatitis as a major public health concern by 2030, the World Health Organization (WHO) has set a goal of treating 80% of eligible CHC with antiviral therapy. [2] Unfortunately, treatment rates are far below this number. Several U.S. based studies report treatment rates with pegylated-interferon (PEG-IFN) and ribavirin (RBV) that range from nine to 36%. [3] [4] [5] [6] [7] In their report the WHO also estimates that under 1% of treatment eligible CHC patients worldwide have received antiviral therapy. [2] These low treatment rates are likely due to both PEG-IFN/RBV related toxicities and contraindications as well as systems-level barriers such as medication cost, insurance reimbursement, and appropriate specialist follow up. Newer direct acting antiviral agents (DAAs) will likely lower barriers related to treatment eligibility and patient/provider willingness to undergo treatment, but systems-level barriers will likely persist. [8, 9] In addition, it is unclear how treatment rates and barriers vary worldwide where patient populations and healthcare practices differ. As CHC becomes a more easily cured disease, it becomes increasingly important to understand where best to direct our resources to improve access to care.
Our aim was to perform a systematic review of available data to estimate treatment rates for CHC worldwide.
Materials and methods

Data sources and searches
Inclusion and exclusion criteria
We included original studies with ! 25 CHC patients with available antiviral treatment rates. Treatment was defined by receipt of interferon, PEG-IFN, RBV, or DAA-based therapies. Exclusion criteria included studies of populations from randomized control trials and studies of specialized populations including renal hemodialysis centers, human immunodeficiency virus (HIV) clinics, or drug rehabilitation programs. We also excluded studies of cohorts with high rates (! 10%) of HIV and/or hepatitis B co-infection. In the case of studies with overlapping patient populations, we excluded abstracts at major liver meetings if there was a corresponding published manuscript. If multiple manuscripts were published from a similar patient database then we included the study with the largest number of patients.
Study selection and study extraction
Four authors (PV, MJ, PN, ML) independently assessed study titles and abstracts for eligibility (Fig 1) . Studies that were considered eligible were then selected for full-text review. The authors then extracted individual study characteristics, patient treatment and eligibility rates, and patient medical and demographic data using a standardized case report form. Any discrepancies were resolved by discussion with the authors including the senior author (MN).
Study definitions
Population-based studies were defined as those that queried patients from national or regionwide databases/registries and did not recruit from a distinct number of clinics or hospitals. Advanced fibrosis was defined by the presence of cirrhosis or by a score of F3 or F4 on the Metavir scale. [11] Studies were further characterized by type of CHC treatment data collection: patient questionnaires, individual clinical chart review, and electronic query of administrative databases (i.e. pharmaceutical prescription or national insurance databases).
Study quality assessment
Study quality was assessed using a scoring system adapted after a modified Newcastle-Ottawa Quality Assessment scale. [12] Two authors (MLY, JFH) scored each study by three criteria: selection (maximum of five points assessing representativeness of the study population, sample size, and ascertainment of HCV exposure), comparability (maximum of one point), and outcome (maximum of three points assessing for reliability of HCV treatment and the statistical test used). As defined by prior studies, a score of seven or more was considered a "good" quality study. [13] 
Statistical analysis
We analyzed pooled treatment rates with corresponding 95% confidence intervals (CIs) using random-effects models and odds ratios (OR) for sub-analyses comparing groups within studies. We assessed for study heterogeneity with χ 2 -based Cochrane Q-statistic with p 0.1 and I 2 ! 50% as measures for substantial study heterogeneity in our models. Multiple separate meta-analyses were performed on study-level characteristics including study region, quality assessment scores, type of therapy studied, patient recruitment period, and data collection methodology. Multivariable random-effects meta-regression on study-level characteristics were also performed to explain any observed heterogeneity in CHC treatment rates. All statistical tests were were performed using Comprehensive Meta-Analysis, version 3 (Biostat, Englewood, New Jersey, USA).
As shown in Table 1, a total of 39 studies with 476,443 CHC patients (37 articles and 2 abstracts) met eligibility criteria and were included in our primary meta-analyses. [3, 4, 6, 7, Based on the modified Newcastle-Ottawa quality score for cross-sectional studies, the mean score of our 39 studies was seven (S1 Table) . Over half of the studies (22/39, 56%) were considered good quality, as defined by a quality score of seven or higher. [13] Pooled CHC treatment rates and by patient-level characteristics across studies
The overall pooled treatment rate was 25.5% (CI: 21.1-30.5%) and there was significant heterogeneity (I 2 = 99.8, p < 0.001) (Fig 2) . On a sub-analysis of eight studies with available data, HCV genotype 1 were less likely to be treated than non-HCV genotype 1 patients (OR = 0.7, CI: 0.63-0.78, p < 0.001) (S2 Table) . There was no significant difference in treatment rates for patients with advanced fibrosis vs. without fibrosis (OR = 1.27, p = 0.39) or males vs. females (OR = 0.88, p = 0.14). 
Treatment rates by region
Treatment rates by data collection methods
Treatment rates were highest when studies collected treatment data by medical chart review (29.8%) and patient questionnaire (30.3%) as done in many studies from referral centers, as compared to electronic query and extraction of population-based administrative databases (11.1%, p < 0.001).
Treatment rates by therapy type
Studies that examined only CHC patients treated with triple therapies including boceprevir or telaprevir did not report higher treatment rates than those that reported treatment rates with dual therapies (32% for triple therapy vs. 25.2% for dual therapy studies, p = 0.61). Random-effects meta-regression of study characteristics Table 2 shows the meta-regression of five study-level factors (practice setting, region, quality assessment score, therapy type, and type of data collection for CHC treatment) testing for sources of heterogeneity of HCV treatment rates.
On meta-regression model practice setting (tertiary vs. population-based, p = 0.04), region (Europe vs. North America p = 0.004), and treatment data collection type (chart review vs. electronic query, p = 0.025) remained significant predictors of heterogeneity.
Treatment eligibility rates
Analysis of twenty-one studies with available data showed a pooled eligibility rate of 52.5% (CI: 45.9-59%), and 60% (CI: 49.2-69.9%) of eligible patients were treated. There was no statistically significant difference in eligibility rates by region (64.5% for Asia/Pacific region, 54.6% for Europe, and 47% for North America, p = 0.48) (Fig 4) . On sub-analysis of treatment rates among eligible patients by region, studies from Europe had higher treatment rates (76.8%), while studies from the Asia/Pacific (53.2%), and North America had lower rates (42.2%, p for overall model = 0.01) (S1 Fig).
Reasons for treatment ineligibility and treatment refusal
Loss to follow up or lack of referral to HCV specialists was the most common reason for no treatment (14.6%, CI: 5.5-33.6%) ( Table 3 ). Other reasons include normal liver tests or lack of significant fibrosis (8.6%, CI: 4.1-17.2%), medical contraindications (11.4%, CI: 6-20.7%), psychiatric contraindications (3.6%, CI: 2.5-5.3%), and active substance abuse (2.8%, CI: 1.2-6.4%). The most common reasons for treatment refusal by eligible patients was concern for treatment side effects (16.2%, CI: 13.3-19.5%), cost or insurance issues (13.8%, CI: 6.4-27.2%), and waiting for better treatment (12.2%, CI: 8.2-17.6%) ( Table 4) .
Discussion
In this systematic review, we found that only one-quarter (25.5%) of CHC patients received antiviral therapy. Fifty-two percent of patients were eligible for treatment and only 60% of these eligible patients received antiviral therapy. In addition, for the 47% of patients who were not eligible for treatment, we found the most common reasons for treatment ineligibility were loss to follow up or lack of referral to HCV specialists. This overall low treatment rate is well below the WHO's goal treatment rate of 80% and demonstrates the importance of proper referral and follow up for CHC patients to receive treatment. [4, 6, 25, 49, 50] While many of the reasons for treatment ineligibility were specific to PEG-IFN + RBV, this issue in linkageto-care is multifactorial and related in part to the asymptomatic nature of CHC but also to a lack of the ability to provide extensive pre-treatment workup including serologic testing and assessment for liver fibrosis and inflammation. [6, 45, [49] [50] [51] We also found no statistical difference in treatment rates with PEG-IFN + RBV combined with first generation DAAs boceprevir or telaprevir (32%) compared to those examining PEG-IFN + RBV alone (25%, p = 0.61). Despite the improved sustained viral response rates, the similar treatment rates with triple therapy were likely reflective of the significant barriers inherent to PEG-IFN + RBV. The use of the well tolerated newer all-oral DAA therapies will likely diminish the barriers related to treatment eligibility and provider/patient acceptance, especially those related to medical and/or psychiatric contraindications. Systematic review of hepatitis C treatment rates and barriers worldwide Another significant barrier to treatment for eligible patients in this study was cost and insurance related. An estimated 14% of treatment-eligible patients declined therapy because of cost or were denied insurance coverage. This is an important point as the evolution of the newer and more expensive interferon free DAA's continues and more drugs enter the market. With the current costs of all-oral DAAs well exceeding that of PEG-IFN-based therapies, the non-treatment rate due to insurance approval and cost may actually rise compared to that from the PEG-IFN era even in high income countries. [52, 53] Furthermore, our pooled treatment rates, while low, are still likely an underestimation of the overall CHC treatment rate considering that many CHC patients remain undiagnosed. As we now have highly effective DAAs, it becomes even more important to identify patients with CHC early in their disease course and also issues in our linkage to specialist care or primary providers comfortable in the management of these patients.
On our meta-analysis of treatment rates by region, Europe had the highest treatment rate (34%), followed by the Asia/Pacific region (28.3%), and finally North America (18.7%). Some of these differences may be attributable to study methodologies which were also important predictors of treatment rate heterogeneity. North America had the highest proportions of population-based studies and also studies that queried HCV treatment electronically both found to be predictors of treatment rate heterogeneity. Population-based studies may have lower treatment rates due to the inclusion of all-comers with CHC: patients evaluated in community clinics and emergency rooms who are not referred to specialists.
However, on our final meta-regression model adjusting for these study methodologies, we found that region (Europe vs. North America) remained a significant source of heterogeneity (p = 0.004). In addition, on a separate analysis, treatment eligibility rates were not significantly different among the 3 geographic regions (47% for North America vs. 65% for Asia/Pacific and 55% for Europe, overall p = 0.48). This suggests that some of the barriers are specific to North America and include insurance reimbursement criteria, and patient-physician preferences.
Small, but potentially significant differences between international guidelines for the use of PEG-IFN and RBV based therapies may also have affected treatment rates. While all three major international guidelines (EASL, AASLD, and APASL) recommend against treating decompensated cirrhotics with interferon-based therapies, the guidelines from AASLD further specify acceptable laboratory parameters: total serum bilirubin < 1.5 g/dL, International Normalized Ratio < 1.5, platelet count < 75,000, and serum albumin > 3.4). [54] In the guidelines published by EASL and APASL many of these laboratory criteria are absent or considered relative contraindications to treatment. [55, 56] The AASLD guidelines also strongly recommend a baseline liver biopsy to assess baseline liver inflammation and fibrosis prior to initiating treatment. [54] In contrast the guidelines from APASL and EASL, published in subsequent years, included other non-invasive methods including transient elastography and blood marker panels as potential substitutes for liver biopsy. [55, 56] Based on this systematic review, there are no studies that directly examined treatment rates and barriers to care with the newer DAA therapies and this is an area that will require further research. One paper, presented by Moon et al., reported a significant increase in treatment prescriptions in 2015 compared to the prior PEG-IFN years. The investigators attributed this large increase to the introduction of 2nd generation DAA therapies into the CHC treatment armament. [57] This is likely a result of the lower treatment threshold of DAA-based therapies: the revised recommendations for DAA therapy from EASL, AASLD, and APASL have recommended considering treatment for all CHC patients including those with decompensated liver disease. [58] [59] [60] Our study does have a few limitations. Several of the sub-analyses included fewer studies so the results should be interpreted with caution. There was also high heterogeneity among our studies, which is due to the variety of patient populations, regional practices, time period of the study, and sample sizes. To address this, we analyzed by subgroups and also attempted to control for confounders through the use of a multivariable meta-regression model. Finally, our results may not be generalizable to certain regions such as Africa and the Middle East due to the lack or relative underrepresentation of studies from these regions. This is concerning because these regions have the largest HCV disease burden in the world. [61] A recent meta-analysis examining operational interventions to enhance chronic viral hepatitis testing and linkage to care found that several simple, inexpensive operational interventions can improve engagement and retention in the cascade of care of patients with chronic viral hepatitis, but further operational research is needed in these regions. [62] Our study is the first systematic review to examine HCV treatment rates for all geographic regions with available data. We found that treatment rates were suboptimal with only 25.5% overall, and only 60% of CHC patients worldwide, who met treatment criteria and did not have any medical or psychiatric contraindication, received treatment before the availability of IFN-free regimens. While these low treatment rates are partly attributable to PEG-IFN and ribavirin, further research efforts are needed to identify and quantify other treatment barriers that may persist in this IFN-free DAA era and especially those related to cost, insurance authorization, and lack of linkage to care with providers familiar with the management of patients with CHC. 
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